SUBSCRIBE
SUBSCRIBE

Gilead Sciences, Inc.

NEWS
Drug Development
High Dose of Gilead and Galapagos’ JAK-Inhibitor Filgotinib Hits the Mark in UC Study
A high dose of filgotinib, the JAK1 inhibitor under long-term development by Gilead Sciences and Galapagos NV, proved effective in a Phase IIb/III study as a treatment for patients with moderately to severely active ulcerative colitis.
May 21, 2020
 · 
2 min read
 · 
Alex Keown
Policy
Biopharma Update on the Novel Coronavirus: May 21
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 21, 2020.
May 21, 2020
 · 
4 min read
 · 
BioSpace Editorial Staff
Policy
Biopharma Update on the Novel Coronavirus: May 18
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 18, 2020.
May 18, 2020
 · 
5 min read
 · 
BioSpace Editorial Staff
Business
Gilead Inks Manufacturing Deals to Make COVID-19 Drug Remdesivir Available in 127 Countries
Gilead stated that the five companies will manufacture the drug for distribution in “low-income and lower-middle-income countries, as well as several upper-middle- and high-income countries.”
May 13, 2020
 · 
3 min read
 · 
Mark Terry
Drug Development
Biopharma Update on the Novel Coronavirus: May 11
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 11, 2020.
May 11, 2020
 · 
4 min read
 · 
BioSpace Editorial Staff
Policy
Biopharma Update on the Novel Coronavirus: May 6
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 6, 2020.
May 6, 2020
 · 
5 min read
 · 
BioSpace Editorial Staff
Biotech Bay
Gilead Outlines Efforts to Expand Global Supply of Remdesivir for COVID-19
On May 5, the company issued a statement describing their efforts.
May 6, 2020
 · 
2 min read
 · 
Mark Terry
Policy
Biopharma Update on the Novel Coronavirus: May 5
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 5, 2020.
May 5, 2020
 · 
6 min read
 · 
BioSpace Editorial Staff
Policy
Biopharma Update on the Novel Coronavirus: May 4
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 4, 2020.
May 4, 2020
 · 
5 min read
 · 
BioSpace Editorial Staff
Load More
  • 2025 BPTW Badge - RBG.png
  • 2024 Best Places to Work
  • 2023 Best Places to Work
  • 2022 Best Places to Work
JOBS
IN THE PRESS
Biotech Bay
European Medicines Agency Validates Marketing Authorization Application for Sacituzumab Govitecan-Hziy for the Treatment of Metastatic Triple-Negative Breast Cancer
March 25, 2021
 · 
10 min read
Business
Gilead and Novo Nordisk Expand NASH Clinical Collaboration
March 18, 2021
 · 
6 min read
Business
Merck to Host Investor Briefing to Discuss Broad HIV Development Program and Newly Announced Collaboration with Gilead
March 15, 2021
 · 
3 min read
Business
Gilead and Merck Announce Agreement to Jointly Develop and Commercialize Long-Acting, Investigational Treatment Combinations of Lenacapavir and Islatravir in HIV
March 15, 2021
 · 
12 min read
Drug Development
Genentech Provides Update on the Phase III REMDACTA Trial of Actemra Plus Veklury in Patients With Severe COVID-19 Pneumonia
March 11, 2021
 · 
8 min read
Drug Development
Gilead’s Investigational Lenacapavir Demonstrates Sustained Long-Acting Efficacy Through Week 26 in Data Presented at CROI
March 9, 2021
 · 
10 min read
Deals
Gilead Sciences Completes Acquisition of MYR GmbH
March 4, 2021
 · 
3 min read
Biotech Bay
Gilead to Present New Data at CROI 2021 Demonstrating the Company’s Commitment to Addressing Urgent Global Health Needs
March 2, 2021
 · 
23 min read
Biotech Bay
Gilead Sciences to Present at Upcoming Investor Conferences
February 18, 2021
 · 
1 min read
Drug Development
Galapagos and Gilead Discontinue ISABELA Phase 3 Trials in IPF
February 10, 2021
 · 
6 min read
Load More